研究单位：[1]Merck Sharp & Dohme LLC[2]Orion Corporation, Orion Pharma[3]Peking University First Hospital-Urology ( Site 0001),Beijing,Beijing,China,100034[4]Tongji Hospital Tongji Medical,Science & Technology ( Site 0002),Wuhan,Hubei,China,430000
研究目的：
The primary objectives of this study are to evaluate the safety and tolerability of MK-5684 in the treatment of male Chinese participants with metastatic castration-resistant prostate cancer (mCRPC) and to characterize the pharmacokinetic profile of MK-5684. There are no formal hypotheses to be tested in this study.
